4724 Stock Overview
Meribank Biotech Co., Ltd manufactures, develops, and stores mesenchymal stem cells in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Meribank Biotech Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$34.90 |
| 52 Week High | NT$53.50 |
| 52 Week Low | NT$27.85 |
| Beta | 0 |
| 1 Month Change | -5.80% |
| 3 Month Change | 1.60% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 12.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4724 | TW Healthcare | TW Market | |
|---|---|---|---|
| 7D | -5.7% | 1.8% | 1.9% |
| 1Y | n/a | -15.9% | 27.8% |
Return vs Industry: Insufficient data to determine how 4724 performed against the TW Healthcare industry.
Return vs Market: Insufficient data to determine how 4724 performed against the TW Market.
Price Volatility
| 4724 volatility | |
|---|---|
| 4724 Average Weekly Movement | 5.8% |
| Healthcare Industry Average Movement | 4.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in TW Market | 8.8% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 4724 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4724's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | n/a | www.meribank.com.tw |
Meribank Biotech Co., Ltd manufactures, develops, and stores mesenchymal stem cells in Taiwan. The company engages in storage of placental umbilical cord mesenchymal stem cells, cord blood hematopoietic stem cells, and immune cells. It is also involved in cell cryopreservation protocol and postpartum nursing services.
Meribank Biotech Co., Ltd Fundamentals Summary
| 4724 fundamental statistics | |
|---|---|
| Market cap | NT$2.48b |
| Earnings (TTM) | -NT$125.35m |
| Revenue (TTM) | NT$234.34m |
10.6x
P/S Ratio-19.8x
P/E RatioIs 4724 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4724 income statement (TTM) | |
|---|---|
| Revenue | NT$234.34m |
| Cost of Revenue | NT$95.47m |
| Gross Profit | NT$138.87m |
| Other Expenses | NT$264.22m |
| Earnings | -NT$125.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 59.26% |
| Net Profit Margin | -53.49% |
| Debt/Equity Ratio | 0% |
How did 4724 perform over the long term?
See historical performance and comparison